+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Ewing Sarcoma Drugs Market - Global Ewing Sarcoma Drugs Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030

  • PDF Icon

    Report

  • 280 Pages
  • September 2023
  • Region: Global
  • Fairfield Market Research
  • ID: 5887168
Description Jump to:

Ewing Sarcoma Drugs Market Gains Momentum with Expected 5% CAGR, Surpassing $0.3 Billion by 2030

The global Ewing sarcoma drugs market is on a trajectory of significant growth, with a promising Compound Annual Growth Rate (CAGR) of 5% projected during the period 2023 to 2030, according to the latest market analysis. The market, focused on developing and commercializing drugs for treating Ewing sarcoma, an aggressive bone cancer primarily affecting children and young adults, is expected to reach a valuation of US$0.3 billion in revenue by the end of 2030.

Ewing sarcoma, characterized by the EWSR1-FLI1 fusion gene, has historically posed challenges due to its rarity and aggressive nature. Standard treatment typically involves surgery, chemotherapy, and radiation therapy. However, despite these treatments, there remains an unmet medical need for more effective and targeted therapies tailored for Ewing sarcoma patients.

Key Findings and Growth Drivers

The report highlights several key findings and growth drivers shaping the Ewing sarcoma drugs market:

  • Advancements in Cancer Research: Advancements in cancer research have led to the development of targeted therapies that inhibit specific genetic mutations and molecular pathways driving Ewing sarcoma. Targeted therapies offer higher precision and reduced toxicity compared to traditional chemotherapy, improving treatment efficacy and patient outcomes.
  • Growing Prevalence of Ewing Sarcoma: The rising prevalence of Ewing sarcoma has led to an increased demand for effective treatment options, spurring investment in research, drug development, and commercialization. Early diagnosis and growing awareness further contribute to research funding and the advancement of potential new therapies.
  • Application in Chemotherapy to Increase: The use of Ewing sarcoma drugs in chemotherapy is expected to rise as a standard treatment, driven by a growing number of cases and the need for combination therapies. Research and development efforts have led to the development of more targeted and less toxic chemotherapy drugs for Ewing sarcoma.
  • Hospitals Hold Maximum Opportunities: Hospitals, particularly specialized cancer treatment centers, are the primary end users of Ewing sarcoma drugs. These centers provide comprehensive care and dedicated teams of oncologists experienced in managing Ewing sarcoma cases.
  • Growth Opportunities Across Regions: North America leads the market, benefiting from advanced healthcare infrastructure and a high incidence of Ewing sarcoma. Meanwhile, the Asia Pacific region is witnessing significant growth, driven by rising disease prevalence and investments in healthcare infrastructure.

Challenges in Development Costs

Despite the promising growth prospects, the Ewing sarcoma drugs market faces challenges, primarily related to the high development costs associated with rare diseases. Developing drugs for Ewing sarcoma requires substantial financial investments and involves a prolonged development timeline, which may hinder market expansion.

Key Market Players

Some of the prominent players in the Ewing sarcoma drugs market include Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Novartis AG, Johnson and Johnson, Inc., Abbott Laboratories, GlaxoSmithKline plc, Bayer AG, AstraZeneca, and Pfizer Inc.


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Ewing Sarcoma Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2022
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Ewing Sarcoma Treatment Market Outlook, 2018 - 2030
3.1. Global Ewing Sarcoma Treatment Market Outlook, by Tumour Type, Value (US$ Bn), 2018 - 2030
3.1.1. Key Highlights
3.1.1.1. Bone Tumour
3.1.1.2. Peripheral Primitive Neuroectodermal Tumour
3.1.1.3. Askin Tumour
3.1.1.4. Soft Tissue Tumour
3.2. Global Ewing Sarcoma Treatment Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
3.2.1. Key Highlights
3.2.1.1. Chemotherapy
3.2.1.2. Surgery
3.2.1.3. Radiation
3.2.1.4. Others
3.3. Global Ewing Sarcoma Treatment Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
3.3.1. Key Highlights
3.3.1.1. Hospital
3.3.1.2. Specialty Clinic
3.3.1.3. Homecare
3.3.1.4. Others
3.4. Global Ewing Sarcoma Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2030
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Ewing Sarcoma Treatment Market Outlook, 2018 - 2030
4.1. North America Ewing Sarcoma Treatment Market Outlook, by Tumour Type, Value (US$ Bn), 2018 - 2030
4.1.1. Key Highlights
4.1.1.1. Bone Tumour
4.1.1.2. Peripheral Primitive Neuroectodermal Tumour
4.1.1.3. Askin Tumour
4.1.1.4. Soft Tissue Tumour
4.2. North America Ewing Sarcoma Treatment Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
4.2.1. Key Highlights
4.2.1.1. Chemotherapy
4.2.1.2. Surgery
4.2.1.3. Radiation
4.2.1.4. Others
4.3. North America Ewing Sarcoma Treatment Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
4.3.1. Key Highlights
4.3.1.1. Hospital
4.3.1.2. Specialty Clinic
4.3.1.3. Homecare
4.3.1.4. Others
4.3.2. Market Attractiveness Analysis
4.4. North America Ewing Sarcoma Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
4.4.1. Key Highlights
4.4.1.1. U.S. Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
4.4.1.2. U.S. Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
4.4.1.3. U.S. Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
4.4.1.4. Canada Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
4.4.1.5. Canada Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
4.4.1.6. Canada Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Ewing Sarcoma Treatment Market Outlook, 2018 - 2030
5.1. Europe Ewing Sarcoma Treatment Market Outlook, by Tumour Type, Value (US$ Bn), 2018 - 2030
5.1.1. Key Highlights
5.1.1.1. Bone Tumour
5.1.1.2. Peripheral Primitive Neuroectodermal Tumour
5.1.1.3. Askin Tumour
5.1.1.4. Soft Tissue Tumour
5.2. Europe Ewing Sarcoma Treatment Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
5.2.1. Key Highlights
5.2.1.1. Chemotherapy
5.2.1.2. Surgery
5.2.1.3. Radiation
5.2.1.4. Others
5.3. Europe Ewing Sarcoma Treatment Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
5.3.1. Key Highlights
5.3.1.1. Hospital
5.3.1.2. Specialty Clinic
5.3.1.3. Homecare
5.3.1.4. Others
5.3.2. Market Attractiveness Analysis
5.4. Europe Ewing Sarcoma Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
5.4.1. Key Highlights
5.4.1.1. Germany Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
5.4.1.2. Germany Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
5.4.1.3. Germany Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
5.4.1.4. U.K. Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
5.4.1.5. U.K. Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
5.4.1.6. U.K. Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
5.4.1.7. France Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
5.4.1.8. France Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
5.4.1.9. France Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
5.4.1.10. Italy Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
5.4.1.11. Italy Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
5.4.1.12. Italy Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
5.4.1.13. Turkey Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
5.4.1.14. Turkey Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
5.4.1.15. Turkey Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
5.4.1.16. Russia Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
5.4.1.17. Russia Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
5.4.1.18. Russia Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
5.4.1.19. Rest of Europe Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
5.4.1.20. Rest of Europe Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
5.4.1.21. Rest of Europe Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Ewing Sarcoma Treatment Market Outlook, 2018 - 2030
6.1. Asia Pacific Ewing Sarcoma Treatment Market Outlook, by Tumour Type, Value (US$ Bn), 2018 - 2030
6.1.1. Key Highlights
6.1.1.1. Bone Tumour
6.1.1.2. Peripheral Primitive Neuroectodermal Tumour
6.1.1.3. Askin Tumour
6.1.1.4. Soft Tissue Tumour
6.2. Asia Pacific Ewing Sarcoma Treatment Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
6.2.1. Key Highlights
6.2.1.1. Chemotherapy
6.2.1.2. Surgery
6.2.1.3. Radiation
6.2.1.4. Others
6.3. Asia Pacific Ewing Sarcoma Treatment Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
6.3.1. Key Highlights
6.3.1.1. Hospital
6.3.1.2. Specialty Clinic
6.3.1.3. Homecare
6.3.1.4. Others
6.3.2. Market Attractiveness Analysis
6.4. Asia Pacific Ewing Sarcoma Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
6.4.1. Key Highlights
6.4.1.1. China Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
6.4.1.2. China Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
6.4.1.3. China Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
6.4.1.4. Japan Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
6.4.1.5. Japan Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
6.4.1.6. Japan Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
6.4.1.7. South Korea Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
6.4.1.8. South Korea Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
6.4.1.9. South Korea Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
6.4.1.10. India Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
6.4.1.11. India Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
6.4.1.12. India Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
6.4.1.13. Southeast Asia Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
6.4.1.14. Southeast Asia Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
6.4.1.15. Southeast Asia Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
6.4.1.16. Rest of Asia Pacific Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
6.4.1.17. Rest of Asia Pacific Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
6.4.1.18. Rest of Asia Pacific Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Ewing Sarcoma Treatment Market Outlook, 2018 - 2030
7.1. Latin America Ewing Sarcoma Treatment Market Outlook, by Tumour Type, Value (US$ Bn), 2018 - 2030
7.1.1. Key Highlights
7.1.1.1. Bone Tumour
7.1.1.2. Peripheral Primitive Neuroectodermal Tumour
7.1.1.3. Askin Tumour
7.1.1.4. Soft Tissue Tumour
7.2. Latin America Ewing Sarcoma Treatment Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
7.2.1. Key Highlights
7.2.1.1. Chemotherapy
7.2.1.2. Surgery
7.2.1.3. Radiation
7.2.1.4. Others
7.3. Latin America Ewing Sarcoma Treatment Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
7.3.1. Key Highlights
7.3.1.1. Hospital
7.3.1.2. Specialty Clinic
7.3.1.3. Homecare
7.3.1.4. Others
7.3.2. Market Attractiveness Analysis
7.4. Latin America Ewing Sarcoma Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
7.4.1. Key Highlights
7.4.1.1. Brazil Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
7.4.1.2. Brazil Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
7.4.1.3. Brazil Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
7.4.1.4. Mexico Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
7.4.1.5. Mexico Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
7.4.1.6. Mexico Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
7.4.1.7. Argentina Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
7.4.1.8. Argentina Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
7.4.1.9. Argentina Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
7.4.1.10. Rest of Latin America Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
7.4.1.11. Rest of Latin America Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
7.4.1.12. Rest of Latin America Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Ewing Sarcoma Treatment Market Outlook, 2018 - 2030
8.1. Middle East & Africa Ewing Sarcoma Treatment Market Outlook, by Tumour Type, Value (US$ Bn), 2018 - 2030
8.1.1. Key Highlights
8.1.1.1. Bone Tumour
8.1.1.2. Peripheral Primitive Neuroectodermal Tumour
8.1.1.3. Askin Tumour
8.1.1.4. Soft Tissue Tumour
8.2. Middle East & Africa Ewing Sarcoma Treatment Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
8.2.1. Key Highlights
8.2.1.1. Chemotherapy
8.2.1.2. Surgery
8.2.1.3. Radiation
8.2.1.4. Others
8.3. Middle East & Africa Ewing Sarcoma Treatment Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
8.3.1. Key Highlights
8.3.1.1. Hospital
8.3.1.2. Specialty Clinic
8.3.1.3. Homecare
8.3.1.4. Others
8.3.2. Market Attractiveness Analysis
8.4. Middle East & Africa Ewing Sarcoma Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
8.4.1. Key Highlights
8.4.1.1. GCC Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
8.4.1.2. GCC Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
8.4.1.3. GCC Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
8.4.1.4. South Africa Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
8.4.1.5. South Africa Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
8.4.1.6. South Africa Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
8.4.1.7. Egypt Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
8.4.1.8. Egypt Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
8.4.1.9. Egypt Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
8.4.1.10. Nigeria Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
8.4.1.11. Nigeria Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
8.4.1.12. Nigeria Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
8.4.1.13. Rest of Middle East & Africa Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
8.4.1.14. Rest of Middle East & Africa Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
8.4.1.15. Rest of Middle East & Africa Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Manufacturer vs Type Heatmap
9.2. Company Market Share Analysis, 2022
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Merck & Co., Inc.
9.4.1.1. Company Overview
9.4.1.2. Tumour Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. F. Hoffmann-La Roche Ltd.
9.4.2.1. Company Overview
9.4.2.2. Tumour Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Bristol-Myers Squibb Company
9.4.3.1. Company Overview
9.4.3.2. Tumour Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. Novartis AG
9.4.4.1. Company Overview
9.4.4.2. Tumour Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Johnson and Johnson, Inc.
9.4.5.1. Company Overview
9.4.5.2. Tumour Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Abbott Laboratories
9.4.6.1. Company Overview
9.4.6.2. Tumour Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. GlaxoSmithKline plc
9.4.7.1. Company Overview
9.4.7.2. Tumour Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. Bayer AG
9.4.8.1. Company Overview
9.4.8.2. Tumour Portfolio
9.4.8.3. Business Strategies and Development
9.4.9. AstraZeneca
9.4.9.1. Company Overview
9.4.9.2. Tumour Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development
9.4.10. Pfizer, Inc.
9.4.10.1. Company Overview
9.4.10.2. Tumour Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Johnson and Johnson, Inc.
  • Abbott Laboratories
  • GlaxoSmithKline plc
  • Bayer AG
  • AstraZeneca
  • Pfizer, Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Global Ewing's Sarcoma Treatment Market 2024-2028 - Product Image

Global Ewing's Sarcoma Treatment Market 2024-2028

  • Report
  • 158 Pages
  • Global
From
Ewing Sarcoma - Global Clinical Trials Review, 2024 - Product Image

Ewing Sarcoma - Global Clinical Trials Review, 2024

  • Clinical Trials
  • 294 Pages
  • Global
From
Ewing Sarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape - Product Image

Ewing Sarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

  • Report
  • 74 Pages
  • Global
From
Global Sarcoma Drugs Market by Indication (Angiosarcoma, Chondrosarcoma, Dermatofibrosarcoma Protuberans), Drugs (Chemotherapy Drugs, Immunotherapy Drugs, Targeted Drug Therapy), Sales Channel, End-User - Forecast 2024-2030 - Product Image

Global Sarcoma Drugs Market by Indication (Angiosarcoma, Chondrosarcoma, Dermatofibrosarcoma Protuberans), Drugs (Chemotherapy Drugs, Immunotherapy Drugs, Targeted Drug Therapy), Sales Channel, End-User - Forecast 2024-2030

  • Report
  • 195 Pages
  • Global
From
Sarcoma Drugs - Global Strategic Business Report - Product Image

Sarcoma Drugs - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.